Results 81 to 90 of about 19,933,051 (310)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression

Cell Death and Disease, 2021
Dysregulation of transforming growth factor-beta (TGFβ) signaling has been implicated in liver carcinogenesis with both tumor promoting and inhibiting activities.
Haichuan Wang, Pan Wang, Meng Xu, Xinhua Song, Hong Wu, Matthias Evert, Diego F. Calvisi, Yong Zeng, Xin Chen   +8 more
doaj   +1 more source

Direct Activation of HSP90A Transcription by c-Myc Contributes to c-Myc-induced Transformation [PDF]

Journal of Biological Chemistry, 2004
The c-myc proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and differentiation and implicated in inducing tumorigenesis. Understanding the function of c-Myc and its role in cancer depends upon the identification of c-Myc target genes.
Teng, Shu-Chun, Chen, Yung-Yi, Su, Yi-Ning, Chou, Po-Chien, Chiang, Yu-Chi, Tseng, Shun-Fu, Wu, Kou-Juey   +6 more
openaire   +2 more sources

Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis-0

, 2011
Copyright information:Taken from "Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis"BMC Biology 2004;2():26-26.Published online 21 Dec 2004PMCID:PMC544575.Copyright ...
Sevasti Zervou (71022), Stella Pelengaris (71018), Linda Cheung (71020), Michael Khan (71023), Sylvie Abouna (71019), Vasiliki Ifandi (71021)   +5 more
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

A novel mechanism by which c-MYC is aberrantly activated by epigenetic silencing of its antisense lncRNA in colon cancer

Frontiers in Genetics
BackgroundProto-oncogenes are abnormally activated in nearly all types of tumors. However, the epigenetic mechanism of proto-oncogene activation has not yet been well elucidated.MethodsThe present study involved the construction of a double-stranded cDNA
Xuming Hu, Xuming Hu, Xuming Hu, Ye Wei, Meiying Zhang, Chunfeng Dou, Liping Wang, Gul Zaib, Huixian Wu, Wang Guo, Xiaoyuan Wang, Shihao Chen, Qi Xu, Qi Xu, Qi Xu, Mingzhou Guo, Hengmi Cui, Hengmi Cui, Hengmi Cui, Hengmi Cui   +19 more
doaj   +1 more source

C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.

PLoS ONE, 2014
ObjectivesVarious studies have investigated the prognostic value of C-MYC aberrations in diffuse large B-cell lymphoma (DLBCL). However, the role of C-MYC as an independent prognostic factor in clinical practice remains controversial. A systematic review
Kuangguo Zhou, Danmei Xu, Yang Cao, Jue Wang, Yunfan Yang, Mei Huang   +5 more
doaj   +1 more source

c-Myc oncoprotein function

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1991
Genetic alterations of the c-myc locus in various malignancies and the ability of c-myc to transform cultured cells and induce tumors in transgenic animals attest to its central role in many neoplasms. By dissecting the c-Myc protein, a number of critical functional domains of c-Myc have been identified and characterized; these findings suggest a model
openaire   +2 more sources

Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription [PDF]

Oncogene, 2012
The transcription factor c-Myc has a critical role in cell proliferation and growth. The control of ribosome biogenesis by c-Myc through the regulation of transcription mediated by all three RNA polymerases is essential for c-Myc-driven proliferation. Specifically, in the nucleolus, c-Myc has been shown to be recruited to ribosomal DNA and activate RNA
Z, Li, S R, Hann
openaire   +2 more sources

Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis-1

, 2011
Copyright information:Taken from "Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis"BMC Biology 2004;2():26-26.Published online 21 Dec 2004PMCID:PMC544575.Copyright ...
Sevasti Zervou (71022), Stella Pelengaris (71018), Linda Cheung (71020), Michael Khan (71023), Sylvie Abouna (71019), Vasiliki Ifandi (71021)   +5 more
core   +1 more source